Hours after filing $150M IPO, Tricida shares positive PhIII trial results on CKD drug
South San Francisco drugmaker Tricida signaled plans late Monday to raise $150 million in an IPO, stockpiling cash to fuel the company’s NDA filing and commercial launch of its late-stage chronic kidney disease drug. Then hours after its filing, the company announced positive Phase III data, with its drug meeting all primary and secondary endpoints.
The company’s lead drug is TRC101, a novel polymer that’s served up orally as a suspension in water to treat metabolic acidosis in CKD patients. It’s designed to bind to hydrochloric acid in the GI tract, then remove the acid via excretion — thereby decreasing the amount of acid in the body and boosting blood bicarbonate.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.